FGAM
HRTX icon

Financial Gravity Asset Management’s Heron Therapeutics HRTX Stock Holding History

Financial Gravity Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75
Closed -$209 – 1896
2024
Q1 		$209 Buy
+75
New +$189 ﹤0.01% 1614
2023
Q3 		– Sell
-1
Closed -$46 – 1477
2023
Q2 		$46 Buy
+1
New +$2 ﹤0.01% 1408
2023
Q1 		– Sell
-3
Closed -$98 – 1372
2022
Q4 		$98 Buy
+3
New +$10 ﹤0.01% 1109
2019
Q2 		– Sell
-66
Closed -$2K – 1421
2019
Q1 		$2K Buy
+66
New +$1.73K ﹤0.01% 949

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Financial Gravity Asset Management's HRTX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 75 shares — an estimated $209 sold.

Financial Gravity Asset Management first reported a position in HRTX in Q1 2019 and held it in 4 quarters. The position peaked at $2K in Q1 2019. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 75 Heron Therapeutics shares in Q2 2024, an estimated $209.
  • Financial Gravity Asset Management first reported a position in Heron Therapeutics in Q1 2019 and held it in 4 quarters.
  • Financial Gravity Asset Management's Heron Therapeutics position peaked at $2K in Q1 2019.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.